Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 3
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA) BJMBR
Zhao,W.P.; Zhang,Z.G.; Li,X.D.; Yu,D.; Rui,X.F.; Li,G.H.; Ding,G.Q..
We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA. Sixty-four patients with category IIIA CPPS were randomized into two groups of 32 subjects each. One group was treated with celecoxib (200 mg daily) and the other with placebo. All patients underwent treatment for 6 weeks and were evaluated clinically before (baseline) and after 1, 2, 4, 6, and 8 weeks of treatment. The evaluation included the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and a subjective global assessment (SGA). Repeated measures analysis of variance was used to evaluate treatment and time effects and their interaction. A decrease (means ± SD) in total NIH-CPSI score from 23.91 ± 5.27 to...
Tipo: Info:eu-repo/semantics/other Palavras-chave: Prostatitis; Chronic pelvic pain syndrome; Cyclooxygenase inhibitors.
Ano: 2009 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2009001000015
Imagem não selecionada

Imprime registro no formato completo
Comparison of etoricoxib and indomethacin for the treatment of experimental periodontitis in rats BJMBR
Azoubel,M.C.F.; Menezes,A.M.A.; Bezerra,D.; Oriá,R.B.; Ribeiro,R.A.; Brito,G.A.C..
We investigated the effect of etoricoxib, a selective cyclooxygenase-2 inhibitor, and indomethacin, a non-selective cyclooxygenase inhibitor, on experimental periodontitis, and compared their gastrointestinal side effects. A ligature was placed around the second upper left molars of female Wistar rats (160 to 200 g). Animals (6 per group) were treated daily with oral doses of 3 or 9 mg/kg etoricoxib, 5 mg/kg indomethacin, or 0.2 mL saline, starting 5 days after the induction of periodontitis, when bone resorption was detected, until the sacrifice on the 11th day. The weight and survival rate were monitored. Alveolar bone loss (ABL) was measured as the sum of distances between the cusp tips and the alveolar bone. The gastric mucosa was examined...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Alveolar bone loss; Inflammation; Periodontitis; Cyclooxygenase inhibitors; Etoricoxib; Indomethacin.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000100015
Imagem não selecionada

Imprime registro no formato completo
The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal BJMBR
Benetello,V.; Sakamoto,F.C.; Giglio,F.P.M.; Sakai,V.T.; Calvo,A.M.; Modena,K.C.S.; Colombini,B.L.; Dionísio,T.J.; Lauris,J.R.P.; Faria,F.A.C.; Santos,C.F..
We compared the clinical efficacy of orally administered valdecoxib and piroxicam for the prevention of pain, trismus and swelling after removal of horizontally and totally intrabony impacted lower third molars. Twenty-five patients were scheduled to undergo removal of symmetrically positioned lower third molars in two separate appointments. Valdecoxib (40 mg) or piroxicam (20 mg) was administered in a double-blind, randomized and crossed manner for 4 days after the surgical procedures. Objective and subjective parameters were recorded for comparison of postoperative courses. Both agents were effective for postoperative pain relief (N = 19). There was a similar mouth opening at suture removal compared with the preoperative values (86.14 ± 4.36 and 93.12 ±...
Tipo: Info:eu-repo/semantics/article Palavras-chave: Acute postoperative pain; Cyclooxygenase inhibitors; Lower third molar; Non-steroidal anti-inflammatory drugs; Piroxicam; Valdecoxib.
Ano: 2007 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2007000800015
Registros recuperados: 3
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional